Synthetic Vaccine Is Safer, More Stable

Scientists develop a safer vaccine for foot-and-mouth disease by reproducing the protein shells that encase the disease-causing virus.

Written byDan Cossins
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Structure of the foot-and-mouth disease virusTHE PIRBRIGHT INSTITUTEBritish researchers have created an entirely synthetic vaccine for the animal affliction foot-and-mouth disease, according to a study out this week in PLOS Pathogens. The vaccine comprises only a structural mimic of the protein shell of the virus that causes the disease, and thus contains no genetic material, rendering it unable to infect animals. The synthetic capsid has also been engineered for enhanced stability, so it lasts longer outside of cold storage and will therefore be easier to distribute in the poor, hot countries where foot and mouth is endemic.

The vaccine is expected to be available to farmers in 6 to 8 years, reported Nature. But if the method proves successful when scaled for commercial production, it could be used to create safer and more practical synthetic vaccines for human diseases caused by similar viruses, including polio, which remains a formidable problem in the developing world.

“This work will have a broad and enduring impact on vaccine development, and the technology should be transferable to other viruses from the same family,” study coauthor Dave Stuart, a structural biologist at the University of Oxford, told BBC News.

The research was carried out in response to an outbreak of foot-and-mouth that devastated farms in the United Kingdom in 2001. Almost 10 million livestock animals had to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies